It should be noted that when DLTPT was combined with immunotherapeutic agent like anti-PD-L1 (programmed death ligand-1), the tumour growth was inhibited significantly, inducing immune responses against lung metastatic tumour model in vivo [345]. The gene discussed is CD274; the disease is neoplasm.